Fenster schließen  |  Fenster drucken

[posting]60588387[/posting]Teresas, du findest es doch immer so toll, dass du persönliche Mails vom CEO bekommst. Und diese dann nicht hinterfragst.

Anbei eine Mail aus diesem Forum aus dem Januar 2017:
....profitable before end of 2017

Wo liegt der Fehler für dieses nicht Erreichen des Zieles? Ich würde mal sagen, primär am CEO!

Und jetzt kommst du!


djanzen@aequuspharma.ca Jan 6 at 10:13 PM

Hello XXX and Happy New Year… Thanks for your email. The share price has been a negative surprise over the last few months. The business is going well, sales are growing and we expect additional commercial deals for revenue generating products to be announced this quarter. We also are about to start the second clinical trial for our transdermal Abilify product this month and our partner Corium has begun work on the next two transdermal programs. We have a lot of confidence in the business model and expect big things in 2017. Tax loss selling hurt the share price in December but in general the share price has been weaker than I expected. I personally bought 1million shares in 2016 and plan to buy more once I come out of a trading blackout. Our goal is to be profitable before the end of 2017 which at that point will remove the requirement for going to investors for financings. Happy to chat if you would like to have a phone call… Best, Doug Janzen Chairman and CEO / CoFounder Aequus Pharmaceuticals
 
aus der Diskussion: AQS.V (Mkap c$13.5 M) 2 Produkte am Markt + 3 weitere kurz vor Zulassungsantrag
Autor (Datum des Eintrages): steinbock1969  (17.05.19 14:49:49)
Beitrag: 2,502 von 4,347 (ID:60590825)
Alle Angaben ohne Gewähr © wallstreetONLINE